Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens.

Article Details

Citation

Copy to clipboard

Maggi P, Bellacosa C, Carito V, Perilli F, Lillo A, Volpe A, Trillo G, Angiletta D, Regina G, Angarano G

Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens.

J Antimicrob Chemother. 2011 Apr;66(4):896-900. doi: 10.1093/jac/dkq507. Epub 2011 Jan 20.

PubMed ID

21393134 [ View in PubMed

]

Abstract

OBJECTIVES: The aim of this study was to evaluate the cardiovascular risk among patients treated for more than 5 years with regimens based on nevirapine or efavirenz. PATIENTS AND METHODS: A total of 276 patients were retrospectively evaluated, 156 of whom were treated with nevirapine and 120 with efavirenz, by examining traditional risk factors and detecting the presence of subclinical carotid lesions with colour-Doppler ultrasonography. RESULTS: When comparing the data at baseline and follow-up in the nevirapine group, total cholesterol, low-density lipoprotein cholesterol (LDLc) and triglycerides showed a significant decrease, while high-density lipoprotein cholesterol increased. Ultrasound data, obtained in a subgroup of 67 patients, did not show significant changes for those treated with nevirapine. In the efavirenz group, total cholesterol, LDLc, triglycerides, glycaemia, body mass index and the number of patients with a pathological ultrasound significantly increased. When comparing the two groups at baseline and follow-up, nevirapine patients had significantly higher values of total cholesterol, LDLc and triglycerides at baseline, while total cholesterol and LDLc differed non-significantly at follow-up; triglycerides became significantly lower in the nevirapine arm with respect to the efavirenz group. Glycaemia was comparable between the two groups at baseline, while it was significantly lower in the nevirapine group at follow-up. The number of pathological ultrasound findings was significantly higher in the efavirenz group at follow-up. CONCLUSIONS: Patients treated with nevirapine demonstrated a better lipid and glucose profile and a lower tendency to develop subclinical atherosclerotic lesions.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Nevirapine	Approved	Total cholesterol	decreased	Nevirapine decreases the level of Total cholesterol in the blood
Nevirapine	Approved	LDL cholesterol	decreased	Nevirapine decreases the level of LDL cholesterol in the blood
Efavirenz	Approved Investigational	LDL cholesterol	increased	Efavirenz increases the level of LDL cholesterol in the blood
Nevirapine	Approved	Triglycerides	decreased	Nevirapine decreases the level of Triglycerides in the blood
Efavirenz	Approved Investigational	Triglycerides	increased	Efavirenz increases the level of Triglycerides in the blood
Nevirapine	Approved	HDL cholesterol	increased	Nevirapine increases the level of HDL cholesterol in the blood
Efavirenz	Approved Investigational	Glucose	increased	Efavirenz increases the level of Glucose in the blood
Efavirenz	Approved Investigational	Total cholesterol	increased	Efavirenz increases the level of Total cholesterol in the blood